Market Access News | pharmaphorum

News

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

News

Zogenix slumps after FDA refuses epilepsy drug file

Zogenix’s only drug candidate is facing a long delay after the FDA refused to accept its marketing application, asking for toxicology data.

News

Group of young multiracial woman with red ribbons in hands are struggling against HIV/AIDS. AIDS awareness concept.

ViiV hopes for blockbuster with HIV drug combo approval

The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on

News

Scotland backs Aimovig for migraine after NICE says no

People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness

News

Celgene files potential blockbuster luspatercept

Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.

News

US drug cost body calls for SMA drug price cuts

A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a

At long last, Amgen/UCB score FDA okay for Evenity

Zogenix slumps after FDA refuses epilepsy drug file

ViiV hopes for blockbuster with HIV drug combo approval

Scotland backs Aimovig for migraine after NICE says no

Celgene files potential blockbuster luspatercept

US drug cost body calls for SMA drug price cuts

AstraZeneca raises guidance on stellar cancer drugs growth

How to meet your physicians where they are online

News

Editor's Picks